



PRESS RELEASE

ADVERTISEMENT

REGULATED INFORMATION – INSIDE INFORMATION

11 JANUARY 2023 – 7.30 am

CARE PROPERTY INVEST

Public limited liability company (naamloze vennootschap)

Public Regulated Real Estate Company under Belgian Law (Public RREC)

(Openbare gereguleerde vastgoedvennootschap naar Belgisch recht / GVV)

Registered office: Horstebaan 3, 2900 Schoten (Belgium),

Enterprise number 0456.378.070 (RLR Antwerp)

(the 'Company')

PUBLIC OFFERING TO SUBSCRIBE TO NEW SHARES REGARDING A CAPITAL INCREASE IN CASH WITHIN THE AUTHORISED CAPITAL WITH IRREDUCIBLE ALLOCATION RIGHTS FOR AN AMOUNT OF MAXIMUM EUR 110.966.496

**THE OFFERING CONSISTS OF A PUBLIC OFFERING TO SUBSCRIBE TO THE NEW SHARES
IN BELGIUM AND WILL BE FOLLOWED BY A PRIVATE PLACEMENT OF THE SCRIPS IN AN
'ACCELERATED BOOKBUILDING' (AN ACCELERATED PRIVATE PLACEMENT WITH
CREATION OF AN ORDER BOOK) CONDUCTED IN THE EEA, THE UNITED KINGDOM AND
SWITZERLAND IN ACCORDANCE WITH REGULATION S UNDER THE US SECURITIES ACT
OF 1933**

REQUEST FOR ADMISSION TO TRADING OF (I) THE NEW SHARES AS OF THEIR ISSUANCE AND (II) THE IRREDUCIBLE ALLOCATION RIGHTS DURING THE SUBSCRIPTION PERIOD, ON THE REGULATED MARKET OF EURONEXT BRUSSELS

WARNING: An investment in shares, trading in irreducible allocation rights and/or acquisition of scrips involves significant risks. Investors are urged to read the entire prospectus, and in particular the risk factors described in Chapter 1 'Risk Factors' of the securities note and in chapter 1 'Risk Factors' of the document amendments to the 2021 annual financial report and in sections B and C of the summary (p. 2-5), before investing in the new shares, trading irreducible allocation rights or acquiring scrips. Any decision to invest in the new shares, to trade irreducible allocation rights or to acquire scrips under the offering must be based on all information provided in the prospectus. Potential investors must be able to bear the economic risk of an investment in the shares, the trading of irreducible allocation rights or the acquisition of scrips and to endure a total or partial loss of their investment.

Schoten, Belgium – Wednesday 11 January 2023

Care Property Invest NV ("CP Invest" or the "Company") announces a capital increase by means of contribution in cash within the authorised capital with cancellation of the statutory preemption right and with granting of irreducible allocation rights to all existing shareholders.

Under the capital increase, it is the intention to issue a maximum of 9.247.208 new shares for a

maximum amount of EUR 110.966.496

The issue price as set by the Company, in consultation with the Joint Global Coordinators, is EUR 12.00 per new share, which represents a discount of 20% compared to the closing price of the shares on 10 January 2023, which was EUR 16.00, adjusted to take into account the estimated value of coupon nr. 16 that will be detached on 11 January 2023 (after trading hours), i.e. EUR 15.00 after such adjustment.

3 irreducible allocation rights give the right to subscribe to 1 new share.

Detachment of coupon nr. 17, that represents the irreducible allocation right: 11 januari 2023 (after trading hours).

Detachment of coupon nr. 16, that represents the right to receive gross dividend for the financial year 2022, to which the new shares will not be entitled: 11 januari 2023 (after trading hours).

Subscription period for the new shares through exercising irreducible allocation rights: from Thursday 12 January 2023 (9.00 am) up to and including Thursday 19 January 2023 (16.00 pm) (Belgian time).

The placement of scrips will in principle take place on Friday 20 January 2023.

ABN AMRO Bank (in cooperation with ODDO BHF in the context of the private placement of scrips) and Belfius Bank are acting as Joint Global Coordinators and Joint Bookrunners in this transaction. Berenberg and KBC Securities are acting as Joint Bookrunners.

Offering

Every existing shareholder will receive one irreducible allocation right per existing share held at the close of the markets on 11 January 2023. The irreducible allocation right is represented by coupon nr. 17 and will be tradable on Euronext Brussels during the subscription period, i.e. from 12 January 2023 (9.00 am) up to and including 19 januari 2023 (16.00 pm) (Belgian time).

Existing shareholders holding irreducible allocation rights and the other holders of irreducible allocation rights can subscribe to the new shares from 12 January 2023 (9.00 am) up to and including 19 January 2023 (16.00 pm) (Belgian time) under the terms and conditions set out in the prospectus at an issue price of EUR 12.00 per new share and at the ratio of 1 new share for 3 irreducible allocation rights.

The offering relates to a maximum of 9.247.208 new shares that will have the same rights as the existing shares, it being understood that they will not participate in the Company's results for the 2022 financial year, but will participate in the Company's results for the current 2023 financial year starting from 1 januari 2023.

The capital increase was decided within the framework of the authorised capital.

Reasons for the offering and use of proceeds

The main objective of the offering is to allow the Company to acquire new financial resources and to increase its equity in order to continue the Company's growth strategy in relation to its real estate portfolio, while maintaining a debt ratio of a maximum of 50% (this does not exclude that this may be exceeded for short periods). The Company's maximum permitted debt ratio under the bank covenants is 60%.

The net proceeds of the offering, if fully subscribed to, are estimated to amount to approximately EUR 108.183.133 (after deduction of the commissions and costs and expenses in connection with the offering to be borne by the Company, as described in Chapter 6.8 of the securities note).

The concrete main purpose of the offering is threefold and consists of allowing the Company to finance the realisation of its pipeline, make additional investments in healthcare real estate in European markets and reduce its debt ratio. The allocations listed below are included in order of importance, although they can be carried out simultaneously.

- *Financing the realisation of investments and developments*

The Company intends to use the net proceeds of the offering, in combination with credit financing where appropriate, to fund the realisation of its investments and developments. At present, the Company has developments on its balance sheet for which an amount of EUR 45.7 million remains to be invested. In addition, there are already announced investments under conditions precedent amounting to EUR 15.9 million. For a description of all the Company's essential investments that are in progress or for which firm commitments have already been made, please refer to chapter 2 'Important Events' of the Report of the Board of Directors' as included in the 2021 annual financial report, and as updated in title 2.1 of the document amendments to the 2021 annual financial report.

- *Additional investments in healthcare real estate in European markets*

In addition, the Company analyses potential investment opportunities on an ongoing basis. These opportunities may include acquisitions of new or existing healthcare real estate properties and development projects. The Company is uncertain whether any of these opportunities will materialise in the short or medium term. As of today, the Company has several potential investment opportunities of various sizes and at various stages of a customary investment trajectory.

The Company expects to use the net proceeds of the offering to acquire a number of new healthcare real estate properties in the countries where it operates at of today: expected to be approximately EUR 20 million in The Netherlands and Belgium, approximately EUR 15 million in Spain and approximately EUR 6 million in Ireland.

The Company cannot give more precise information on these, given their state of affairs, and in particular because today none of these potential investment files already constitute irrevocable and unconditional (material) commitments of the Company.

This growth strategy is part of the Company's activities since the expansion of its business in 2014 into investment properties operated privately.

Assuming full subscription to the offering and based on the debt ratio as at 30 September 2022, this means that new additional investments can be made for EUR 525 million before the debt ratio of 60% is reached (maximum debt ratio allowed under the current bank covenants). In practice, the Company will of course monitor its debt ratio, as well as the availability of existing and development investment opportunities, the evolution of returns on its investments and opportunities for new capital increases.

- *Reduction of the debt ratio*

The Company wishes to use the net proceeds of the offering to reduce its debt ratio below 50% on a sustainable basis. For reasons of efficient liquidity management, and pending their effective use to fund the investment and development pipeline, the net proceeds of the offering will initially be used to repay mainly (at least temporarily) outstanding borrowings under existing revolving credit lines and commercial paper, it being understood that the Company may call for new borrowings under these revolving credit facilities and issue new commercial paper as soon as necessary to

fund its growth considering planned investments. In this way, the net proceeds of the offering combined with the existing undrawn available lines of credit will provide greater borrowing capacity and enable the Company to fund its investment and development pipeline in progress.

As a reminder, the Company's consolidated debt ratio was 47.06% as at 31 December 2021 and 51.56% as at 30 September 2022. Upon full subscription to the offering, the net proceeds are estimated to be approximately EUR 108.183.133 (after deducting the costs and expenses to be borne by the Company in connection with the offering), which will reduce the debt ratio as at 30 September 2022, pro forma, to 41,89% upon full subscription to the offering and if the net proceeds were to be spent in full on repayment of the Company's debts.

The Company will determine, at its discretion, the amounts and timing of its actual expenditure and, consequently, the allocation of the net proceeds of the Offering. This will depend on many factors, such as the evolution of the Company's debt ratio, the availability of suitable investment opportunities, the reaching of agreements on appropriate terms with potential sellers, the net proceeds of the offering and the Company's operating costs and expenses.

Dividend entitlement

All new shares will be issued in accordance with Belgian law and are ordinary shares representing the capital, of the same type as the existing shares, fully paid up, with voting rights and without nominal value.

The new shares will have the same rights as the existing shares, it being understood that as a result of the detachment of coupon nr. 16 on 11 January 2023 they will not participate in the Company's results for the 2022 financial year, but will participate in the Company's results for the current 2023 financial year starting from 1 January 2023.

Barring unforeseen circumstances, the Company foresees a gross dividend for the financial year 2022 of at least EUR 1.00 per share (taking into account the current number of shares). After subtracting withholding tax of 15% this would result in a net dividend of EUR 0,85 per share. For the financial year 2023 the Company foresees, barring unforeseen circumstances, a gross dividend of at least the same amount, being EUR 1,00 per share (taking into account the higher number of shares that will participate in the results of the financial years 2023 as a result of the offering, assuming that the maximum number of new shares will be placed). The prior is obviously subject to the effective result for the financial years 2022 and 2023 and the approval of dividend distribution by the general meeting of the Company.

Issue Price

The issue price amounts to EUR 12.00 per new share and has been determined by the Company in consultation with the Joint Global Coordinators on the basis of the stock market price of the share on the regulated market of Euronext Brussels and taking into account a discount usually granted for this type of transaction and also in light of the valuation of the Company's assets (including its perimeter companies) in accordance with article 48, 1° of the RREC Law.

The issue price is 20% lower than the closing price of the share on the regulated market of Euronext Brussels on 10 January 2023 (which amounted to EUR 16.00, adjusted to take into account the estimated value of coupon nr. 16¹ that is being detached on 11 January 2023 (after trading hours), i.e. EUR 15,00 after such adjustment. Based on that closing price, the theoretical ex-rights price ('TERP') is EUR 14,25, the theoretical value of an irreducible allocation right is EUR 0,75, and the

¹ The Board of Directors of the Company estimates coupon no 16 representing the gross dividend for the 2022 financial year at EUR 1.00 per share. This estimate obviously remains subject to the results of the 2022 financial year and the approval by the ordinary general meeting which will decide on the dividend to be paid out for the 2022 financial year (see also under Chapter 5.3.2 of the securities note).

discount of the issue price compared to TERP is 15,79%.

Subscriptions

Subscription applications can be submitted directly at the counters of Belfius, KBC Bank, CBC Banque and KBC Securities for investors holding client accounts and/or through any other financial intermediary. Investors are invited to inform themselves about possible costs charged by these financial intermediaries.

There may be costs associated with the purchase and sale of irreducible allocation rights. Investors are invited to inform themselves of any costs charged for this purpose by these financial intermediaries.

Shareholders holding their shares in a securities account will automatically be allocated a corresponding number of irreducible allocation rights in the securities account they hold with their financial institution, subject to the restrictions in the prospectus and subject to applicable securities law. They will be informed by their financial institution of the procedure to be followed for the exercise or trading of their irreducible allocation rights.

The existing shareholders who hold their shares in registered form, will need to follow the instructions as noted in the notices that they will receive from the Company (subject to applicable securities laws) and through which they will be informed of the total number of irreducible allocation rights they hold and the procedure that they must follow to exercise or trade their irreducible allocation rights.

Irreducible allocation rights

The irreducible allocation right, represented by coupon nr. 17 attached to the existing shares, will be detached from the existing shares on 11 January 2023 (after trading hours). The irreducible allocation rights can be traded on the regulated market of Euronext Brussels during the subscription period under ISIN-code BE0970182854. Those who have not exercised their irreducible allocation rights by the end of the subscription period, i.e. no later than 19 January 2023 at 16.00 pm (Belgian time), will no longer be able to exercise them after that date.

Private placement of scrips

The (i) irreducible allocation rights that were not exercised on the closing date of the subscription period and (ii) registered irreducible allocation rights (x) for which a properly completed and signed subscription form was not received in time, (y) which have not been transferred by (the financial intermediary of) the shareholder (despite any instruction to do so), or (z) for which the total issue price has not been paid in time (and all of which will thereby be qualified as unexercised irreducible allocation rights), will automatically be converted into an equal number of scrips. These scrips will be offered for sale by the Joint Bookrunners to Belgian and international institutional investors in the European Economic Area, the United Kingdom and Switzerland via an exempt private placement in the form of an 'accelerated bookbuild' (an accelerated private placement with creation of an orderbook) and in accordance with Regulation S under the US Securities Act (the "Private Placement of Scrips").

The Private Placement of Scrips will take place as soon as possible after the closing of the subscription period, in principle on 20 januari 2023. On the date of publication of the press release announcing the results of the subscription with irreducible allocation rights, planned for 20 januari 2023, the Company will request the suspension of the share's trading from the stock market opening until the moment the press release announcing the results of the offering is published.

The buyers of scrips will have to subscribe to the new shares still available at the issue price and

in accordance with the subscription ratio which applies to the subscription by exercise of irreducible allocation rights.

The sale price of the scrips will be set jointly by the Company and the Joint Global Coordinators, based on the results of the 'accelerated bookbuild offering' (an accelerated private placement with creation of an orderbook) within the framework of the Private Placement of Scrips. The net proceeds from the sale of these scrips, after deducting costs, expenses and charges of any kind incurred by the Company as part of the Private Placement of Scrips (the 'Excess Amount'), will be distributed proportionally among all holders of the unexercised irreducible allocation rights (or as such qualified irreducible allocation rights), upon presentation of coupon no. 17, in principle as of 25 January 2023. In the event that the Excess Amount divided by the total number of non-exercised (or qualified as such) irreducible allocation rights amounts to less than EUR 0.01 per scrip, it will not be paid out but will be transferred and granted to the Company.

The results of the Private Placement of Scrips and the Excess Amount will in principle be published on 20 januari 2023 via a press release.

Disclosure of the results

The result of the subscriptions for the new shares resulting from the exercise of the irreducible allocation rights as part of the public offering will be announced on 20 January 2023 via a press release on the Company's website.

The result of the subscriptions for the new shares as a result of conducting the Private Placement of Scrips and the Excess Amount due to the holders of unexercised (or as such qualified) irreducible allocation rights (if any) will be announced on 20 January 2023 via a press release.

Payment and delivery of the new shares

The payment of subscriptions for the new shares resulting from the exercise of dematerialised irreducible allocation rights or scrips, takes place by debiting the subscribers' account, with value date on, in principle, 24 January 2023.

The subscription terms and payment due date for the subscription for the new shares resulting from the exercise of the registered irreducible allocation rights will be communicated to the registered existing shareholders by means of a letter addressed to them. In particular, the issue price for the new shares subscribed, based on registered irreducible allocation rights, must have reached (credited) the bank account specified in the letters to the registered existing shareholders no later than 19 January 2023 at 16.00 pm (Belgian time). This is an absolute requirement in order to be able to proceed with the issue and delivery of the new shares subscribed to via the exercise of registered irreducible allocation rights. In order to make sure that this issue price is received on time, the Company advises the existing shareholders holding their registered shares to give timely instructions to their financial institution for this purpose. The Company will refund late payments.

New shares issued on the basis of registered irreducible allocation rights will be included as registered shares in the Company's share register on or around 24 January 2023. New shares issued on the basis of dematerialised irreducible allocation rights will be delivered in dematerialised form on or around 24 January 2023.

Listing of the new shares

The new shares will in principle be admitted to trading on the regulated market of Euronext Brussels from 24 January 2023. The new shares will be assigned the ISIN code BE0974273055, being the same code as for the existing shares.

Prospectus

Care Property Invest NV

Horstebaan 3
2900 Schoten
BE 0456 378 070 - RPR Antwerpen
Openbare GVV naar Belgisch recht

T +32 3 222 94 94
E info@carepropertyinvest.be
www.carepropertyinvest.be



Care building
in complete confidence.

The prospectus consists of the universal registration document (including all information incorporated by reference therein), the securities note (including all information incorporated by reference therein) and the summary. The Company's annual financial report for the financial year ended on 31 December 2021, as published on 22 April 2022, as amended by the document amendments to the 2021 annual financial report dated 10 January 2023, serves as universal registration document.

The Dutch language version of the universal registration document, the securities note and the summary were approved on 10 January 2023 by the FSMA as competent authority pursuant to Article 20 of the Prospectus Regulation. This approval should not be considered an endorsement of the issuer nor of the quality of the securities to which the prospectus relates. Investors should assess for themselves whether it is appropriate to invest in these securities.

The securities note, the universal registration document, and the summary may be distributed separately. The universal registration document, the securities note and the summary are available in the Dutch and English language. In addition, the summary is available in the French language.

*The prospectus will be made available to investors free of charge as from 11 January 2023 at the Company's registered office (Horstebaan 3, 2900 Schoten, Belgium). The prospectus will also be made available to investors free of charge at (i) ABN AMRO, on its website www.abnamroprivatebanking.be and at its branch office at Borsbeeksebrug 30, 2600 Berchem (Belgium) (NL, FR and ENG), (ii) at Belfius, upon request at the telephone number +32 2 222 12 02 (NL, FR and ENG) and on its website www.belfius.be/CPI2023 (NL, FR and ENG), (iii) at KBC Securities on its website on its websites www.kbc.be/cpi2023 (NL, FR and ENG), www.bolero.be/nl/cpi (NL) and www.bolero.be/fr/cpi (FR). The prospectus can also be consulted on the Company's website
<https://carepropertyinvest.be/investeren/aandeelhoudersstructuur/kapitaalverhoging..> Access to the prospectus via the above websites is subject in each case to the usual restrictions.*

Expected offering timetable

<i>Decision of the Board of Directors to increase the share capital</i>	<i>10 January 2023 (after trading hours)</i>
<i>Board of Directors' determination of the Issue Price / the Subscription ratio / the amount of the Offering</i>	<i>10 January 2023 (after trading hours)</i>
<i>Approval of this prospectus by the FSMA</i>	<i>10 January 2023</i>
<i>Press release announcing the Offering, the modalities of the Offering and the launch of the Subscription Period</i>	<i>11 January 2023 (before trading hours)</i>
<i>Detachment of coupon no. 16 which represents the dividend right for the 2022 financial year, which will not be allocated to the New Shares</i>	<i>11 January 2023 (after trading hours)</i>
<i>Detachment of coupon no. 17 for the exercise of the Irreducible Allocation Right</i>	<i>11 January 2023 (after trading hours)</i>
<i>Making this prospectus available to the public on the Company's website</i>	<i>11 January 2023</i>
<i>Opening date of the Subscription Period</i>	<i>12 January 2023</i>
<i>Deadline by which (i) the Company must receive the subscription forms relating to the registered Irreducible Allocation Rights and (ii) the corresponding Issue Price must have been received (credited) on the bank account specified in the letter to the registered Shareholders</i>	<i>19 January 2023, at 16.00 pm (Belgian time)</i>
<i>Subscription Period Closing Date</i>	<i>19 January 2023</i>
<i>Suspension of trading of the Share (at the Company's request) until the publication of the press release on the results of the Offering (i.e. including the Private Placement)</i>	<i>20 January 2023 (at opening of stock exchange)</i>
<i>Press release on the results of the Public Offering (published on the Company's website)</i>	<i>20 January 2023 (before trading hours)</i>
<i>Private Placement of Scrips</i>	<i>20 January 2023</i>
<i>Press Release on the results of the Offering (i.e. including the Private Placement) and the possible Excess Amount - followed by resumption of trading of the Shares</i>	<i>20 January 2023</i>
<i>Payment of the New Shares subscribed for with dematerialised Irreducible Allocation Rights and Scrips</i>	<i>24 January 2023 (before trading hours)</i>
<i>Establishment of the realisation of the capital increase</i>	<i>24 January 2023 (before trading hours)</i>
<i>Delivery of the New Shares to the subscribers</i>	<i>24 January 2023</i>
<i>Admission to trading of the New Shares on the regulated market of Euronext Brussels</i>	<i>24 January 2023</i>
<i>Press release concerning the capital increase and the new denominator for transparency purposes</i>	<i>24 January 2023 (before trading hours)</i>
<i>Payment of the Excess Amount</i>	<i>As of 25 January 2023</i>

The Company can adjust the dates and times of the capital increase and the periods indicated in the above

Care Property Invest NV

Horstebaan 3
2900 Schoten
BE 0456 378 070 - RPR Antwerpen
Openbare GVV naar Belgisch recht

T +32 3 222 94 94
E info@carepropertyinvest.be
www.carepropertyinvest.be

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SWITZERLAND, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL



Care building
in complete confidence.

timetable and in the prospectus. In that case, the Company will notify Euronext Brussels and will inform the investors on this subject through a press release and on the Company's website. As far as legally required, the Company will additionally publish a supplement to the prospectus.

Care Property Invest NV

Horstebaan 3
2900 Schoten
BE 0456 378 070 - RPR Antwerpen
Openbare GVV naar Belgisch recht

T +32 3 222 94 94
E info@carepropertyinvest.be
www.carepropertyinvest.be

Disclaimer

These written materials are not for distribution in or to persons resident in the United States of America, Australia, Canada, Japan or South Africa. The information contained herein does not constitute an offer of securities for sale in the United States of America, Australia, Canada, Japan or South Africa.

This information is an advertisement and not a prospectus and investors should not purchase or subscribe for any securities referred to in this information except on the basis of information in the prospectus to be published by Care Property Invest NV (the "Company") in due course in connection with the offering (the "Prospectus"). Copies of the Prospectus will, following publication and subject to restrictions set forth in the Prospectus, be available from the Company's registered office at Horstebaan 3, 2900 Schoten, Belgium and on the website (<https://carepropertyinvest.be/investeren/aandeelhoudersstructuur/kapitaalverhoging>) and will also be made available upon request at ABN AMRO Bank N.V., Belfius Bank SA/NV, Joh. Berenberg, Gossler & Co. KG and KBC Securities NV.

This information does not contain a solicitation for money, securities, or other considerations and, if sent in response to the information contained herein, will not be accepted. This announcement contains statements which are "forward-looking statements" or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are warned that none of these forward-looking statements offers any guarantee of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.

The Company's securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or under the laws of any state or other jurisdiction in the United States of America, and may not be offered or sold within the United States of America except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state laws. No public offering of securities will be made in the United States of America.

This information does not constitute an offer or invitation to proceed to an acquisition of or subscription for the Company's securities, nor an offer or invitation to proceed to an acquisition of or subscription for the Company's securities in the United States of America, Australia, Canada, Japan, South Africa, Switzerland (except in the context of a private placement of certain securities with "professional clients" as set out below), the United Kingdom (except in the context of a private placement of certain securities with certain qualified investors as set out below) or any other jurisdiction where such offer or invitation is not allowed without registration or qualification under the applicable legislation of the relevant jurisdiction, or where such offer or invitation does not meet the required conditions under the applicable legislation of the relevant jurisdiction.

Subject to certain limited exceptions, this information and any materials distributed in connection with this information are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of or located in the United States of America, Australia, Canada, Japan, South Africa or any other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

In each Member State of the European Economic Area other than Belgium (each a "Relevant Member State"), this information is only addressed to and is only directed at qualified investors in that Relevant Member State within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended, and any implementing measure in each Relevant

Member State of the EEA (the "Prospectus Regulation").

In Switzerland, this information is directed only at persons qualifying as "professional clients" in accordance with Article 4 iuncto 36 of the Swiss Financial Services Act ("Finanzdienstleistungsgesetz") of 15 June 2018, as amended ("FinSA"). Any investment activity to which this document relates will only be available to and will only be engaged in with, such professional clients. Any person who is not such a professional client should not act or rely on this document or any of its contents. The distribution of this document in other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.

In the United Kingdom, this information is directed only at "qualified investors" as defined in Article 2(e) of the Prospectus Regulation, as amended and transposed into the laws of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 and the European Union (Withdrawal Agreement) Act 2020 who also have the capacity of (i) persons having professional experience in matters relating to investments falling within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), (ii) high net worth entities, etc. falling within Article 49(2)(a) to (d) of the Order, and (iii) any other person to whom it may otherwise lawfully be communicated. Any investment activity to which this document relates will only be available to and will only be engaged in with, such qualified investors. No person who is not such a qualified investor may act or rely on this document or any of its contents.

Any failure to comply with these restrictions may constitute a violation of the laws or regulations of the United States of America, Australia, Canada, Japan, South Africa, Switzerland, the United Kingdom, or any other jurisdiction. The distribution of this information in other jurisdictions than Belgium, may be restricted by laws or regulations applicable in such jurisdictions. All persons in possession of this information must inform themselves about, and comply with, any such restrictions.

An investment in shares entails significant risks. Relevant investors are encouraged to read the Prospectus that is made available on the website of the Company, www.carepropertyinvest.be.

This document is not a prospectus and investors should not subscribe for or purchase any shares referred to herein except on the basis of the information contained in the Prospectus. Potential investors must read the Prospectus before making an investment decision in order to fully understand the potential risks and rewards associated with the decision to invest in the securities. The approval of the Prospectus should not be understood as an endorsement of the securities offered or admitted to trading on a regulated market.

This press release has been translated from Dutch to English. In case of discrepancies between the different versions of this press release, the Dutch version, as approved by the FSMA, will prevail.

For any additional information, please contact:



Filip Van Zeebroeck
CFO – Member of the executive committee
filip.vanzeebroeck@carepropertyinvest.be
T +32 3 222 94 94 - M +32 494 91 10 93
Horstebaan 3, 2900 Schoten
info@carepropertyinvest.be
www.carepropertyinvest.be



Willem Van Gaver
Head of Legal
willem.vangaver@carepropertyinvest.be
T +32 3 222 94 94 - M +32 498 41 61 43
Horstebaan 3, 2900 Schoten
info@carepropertyinvest.be
www.carepropertyinvest.be



Peter Van Heukelom
CEO – Member of the executive committee
peter.vanheukelom@carepropertyinvest.be
T +32 3 222 94 94 - M +32 495 59 82 67
Horstebaan 3, 2900 Schoten
info@carepropertyinvest.be
www.carepropertyinvest.be

About Care Property Invest

Care Property Invest NV/SA is a Public Regulated Real Estate Company (public RREC) under Belgian law. The Company has been listed on Euronext Brussels for over 25 years and invests in high quality healthcare real estate for elderly and disabled people on the European market. Care Property Invest purchases, builds and renovates high-quality healthcare real estate (residential care centers, groups of assisted living apartments, residential complexes for people with a disability, etc.), fully tailored to the needs of the end user and then makes it available to solid healthcare operators on the basis of a long-term contract.

The Company has developed an international portfolio of 143 healthcare projects, spread across Belgium, The Netherlands, Spain and Ireland.

Ticker:	CPINV
ISIN-Code:	BE0974273055
Indexopnames:	<ul style="list-style-type: none">• Belgium BEL Mid (Euronext Brussels)• Euronext Real Estate (Euronext Brussels)• GPR (Global Property Research) General Europe Index



Care building
in complete confidence.

	<ul style="list-style-type: none">GPR (Global Property Research) General Europe Quoted Index (excl. open-end bankfondsen)	
EPRA	EPRA-member since December 2016. In September 2022 the Company received its sixth EPRA BPR Gold Award	
Website	All further information can be found on our website www.carepropertyinvest.be	